These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 35524489)
1. VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse. Heraudet L; Galtier J; Favre S; Peyraud F; Cazaubiel T; Leroy H; Mottal N; Gros FX; Forcade E; Clément L; Dumas PY; Pigneux A; Leguay T Br J Haematol; 2022 Aug; 198(3):523-527. PubMed ID: 35524489 [TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study. Martinelli G; Boissel N; Chevallier P; Ottmann O; Gökbuget N; Rambaldi A; Ritchie EK; Papayannidis C; Tuglus CA; Morris JD; Stein A Eur J Cancer; 2021 Mar; 146():107-114. PubMed ID: 33588145 [TBL] [Abstract][Full Text] [Related]
3. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800 [TBL] [Abstract][Full Text] [Related]
4. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S Cancer Med; 2019 Dec; 8(18):7650-7659. PubMed ID: 31691536 [TBL] [Abstract][Full Text] [Related]
5. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia. Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129 [TBL] [Abstract][Full Text] [Related]
6. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study. Zhou H; Yin Q; Jin J; Liu T; Cai Z; Jiang B; Li D; Sun Z; Li Y; He Y; Ma L; Gao S; Hu J; He A; Du X; Liu D; Zhang X; Ke X; Zhuang J; Han Y; Wang X; Chen Y; Gordon P; Yu D; Zugmaier G; Wang J Hematology; 2022 Dec; 27(1):917-927. PubMed ID: 36000952 [TBL] [Abstract][Full Text] [Related]
8. Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data. Barlev A; Lin VW; Katz A; Hu K; Cong Z; Barber B Adv Ther; 2017 Jan; 34(1):148-155. PubMed ID: 27873237 [TBL] [Abstract][Full Text] [Related]
9. Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia. Gökbuget N; Dombret H; Giebel S; Brüggemann M; Doubek M; Foa R; Hoelzer D; Kim C; Martinelli G; Parovichnikova E; Maria Ribera J; Schoonen M; Tuglus C; Zugmaier G; Bassan R Eur J Haematol; 2020 Apr; 104(4):299-309. PubMed ID: 31876009 [TBL] [Abstract][Full Text] [Related]
10. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Jabbour EJ; Gökbuget N; Kantarjian HM; Thomas X; Larson RA; Yoon SS; Ghobadi A; Topp MS; Tran Q; Franklin JL; Forman SJ; Stein AS Cancer; 2019 Dec; 125(23):4181-4192. PubMed ID: 31433496 [TBL] [Abstract][Full Text] [Related]
11. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis. Topp MS; Stein AS; Gökbuget N; Horst HA; Boissel N; Martinelli G; Kantarjian H; Brüggemann M; Chen Y; Zugmaier G Cancer Med; 2021 Apr; 10(8):2601-2610. PubMed ID: 33734596 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective. Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497 [TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Topp MS; Zimmerman Z; Cannell P; Dombret H; Maertens J; Stein A; Franklin J; Tran Q; Cong Z; Schuh AC Blood; 2018 Jun; 131(26):2906-2914. PubMed ID: 29739753 [TBL] [Abstract][Full Text] [Related]
14. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. Martinelli G; Boissel N; Chevallier P; Ottmann O; Gökbuget N; Topp MS; Fielding AK; Rambaldi A; Ritchie EK; Papayannidis C; Sterling LR; Benjamin J; Stein A J Clin Oncol; 2017 Jun; 35(16):1795-1802. PubMed ID: 28355115 [TBL] [Abstract][Full Text] [Related]
15. Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial. Lu J; Qiu H; Wang Y; Zhou X; Dai H; Lu X; Yang X; Gu B; Hong M; Miao M; Lu R; Wang J; Wu Q; Xue M; Wang Y; Deng A; Shen Y; Liu Y; Dou X; Lei Y; Wu D; Zhu Y; Chen S J Hematol Oncol; 2024 Sep; 17(1):79. PubMed ID: 39218935 [TBL] [Abstract][Full Text] [Related]
16. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment. Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435 [TBL] [Abstract][Full Text] [Related]
17. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Kantarjian HM; Stein AS; Bargou RC; Grande Garcia C; Larson RA; Stelljes M; Gökbuget N; Zugmaier G; Benjamin JE; Zhang A; Jia C; Topp MS Cancer; 2016 Jul; 122(14):2178-85. PubMed ID: 27143254 [TBL] [Abstract][Full Text] [Related]
18. Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Queudeville M; Stein AS; Locatelli F; Ebinger M; Handgretinger R; Gökbuget N; Gore L; Zeng Y; Gokani P; Zugmaier G; Kantarjian HM Cancer; 2023 May; 129(9):1384-1393. PubMed ID: 36829303 [TBL] [Abstract][Full Text] [Related]
19. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623 [TBL] [Abstract][Full Text] [Related]
20. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]